Spinal implant maker NuVasive (NUVA +17%) pops after its Q1 results easily beat estimates,...
Spinal implant maker NuVasive (NUVA +17%) pops after its Q1 results easily beat estimates, coming in at the high end of the expected range. Revenue jumped 21% Y/Y on strong sales of its minimally invasive spinal surgery products. William Blair and Baird both upgrade the stock on the back of the better than expected results.
From other sites
at CNBC.com (Oct 4, 2012)
at CNBC.com (Oct 3, 2012)
at CNBC.com (Jun 28, 2012)
at CNBC.com (Jun 23, 2010)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs